The C677T mutation of the 5,1O-methylenetetrahydrofolate reductase gene is a moderate risk factor for spina bifida in Italy

Raffaella De Franchis, Anna Buoninconti, Claudia Mandato, Antonio Pepe, Maria Pia Sperandeo, Roberto Del Gado, Valeria Capra, Elio Salvaggio, Generoso Andria, Pierpaolo Mastroiacovo

Research output: Contribution to journalArticle

Abstract

Objective: To estimate the risk for spina bifida associated with the common mutation C677T of the MTHFR gene in a country with a relatively low prevalence of NTDs. Design: Case-control study. Subjects: Cases: 203 living patients affected with spina bifida (173 myelomeningocele and 30 lipomeningocele); controls: 583 subjects (306 young adults and 277 unselected newborns) from northern and central-southern Italy. Setting: Cases: Three spina bifida centres; young adult controls: DNA banks; newborn controls: regional neonatal screening centres. Main outcome measures: Prevalence of the C677T genotypes in cases and controls by place of birth; odds ratios for spina bifida and estimated attributable fraction. Results: The prevalence of T/T, T/C, and C/C genotype was 16.6%, 53.7%, and 29.7% in controls and 25.6%, 43.8%, and 30.6% in cases, respectively. We found no differences between type of defect or place of birth. The odds ratio for spina bifida associated with the T/T genotype v C/C plus T/C was 1.73 (95% CI 1.15, 2.59) and the corresponding attributable fraction was 10.8%. No increased risk was found for heterozygous patients (OR = 0.79, 95% CI 0.53-1.18). Conclusion: This study, as well as the meta-analysis we updated, shows that homozygosity for the MTHFR C677T mutation is a moderate risk factor in Europe, and even in Italy where there is a relatively low prevalence of spina bifida. The estimated attributable fraction associated with this risk factor explains only a small proportion of cases preventable by periconceptional folic acid supplementation. Thus, other genes involved in folate-homocysteine metabolism, their interaction, and the interaction between genetic and environmental factors should be investigated further.

Original languageEnglish
Pages (from-to)1009-1013
Number of pages5
JournalJournal of Medical Genetics
Volume35
Issue number12
Publication statusPublished - 1998

Fingerprint

Methylenetetrahydrofolate Reductase (NADPH2)
Spinal Dysraphism
Italy
Mutation
Genes
Genotype
Folic Acid
Young Adult
Odds Ratio
Newborn Infant
Neonatal Screening
Meningomyelocele
Homocysteine
Meta-Analysis
Case-Control Studies
Outcome Assessment (Health Care)
DNA

Keywords

  • Folic acid
  • Meta-analysis
  • MTHFR
  • Spina bifida

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

De Franchis, R., Buoninconti, A., Mandato, C., Pepe, A., Sperandeo, M. P., Del Gado, R., ... Mastroiacovo, P. (1998). The C677T mutation of the 5,1O-methylenetetrahydrofolate reductase gene is a moderate risk factor for spina bifida in Italy. Journal of Medical Genetics, 35(12), 1009-1013.

The C677T mutation of the 5,1O-methylenetetrahydrofolate reductase gene is a moderate risk factor for spina bifida in Italy. / De Franchis, Raffaella; Buoninconti, Anna; Mandato, Claudia; Pepe, Antonio; Sperandeo, Maria Pia; Del Gado, Roberto; Capra, Valeria; Salvaggio, Elio; Andria, Generoso; Mastroiacovo, Pierpaolo.

In: Journal of Medical Genetics, Vol. 35, No. 12, 1998, p. 1009-1013.

Research output: Contribution to journalArticle

De Franchis, R, Buoninconti, A, Mandato, C, Pepe, A, Sperandeo, MP, Del Gado, R, Capra, V, Salvaggio, E, Andria, G & Mastroiacovo, P 1998, 'The C677T mutation of the 5,1O-methylenetetrahydrofolate reductase gene is a moderate risk factor for spina bifida in Italy', Journal of Medical Genetics, vol. 35, no. 12, pp. 1009-1013.
De Franchis R, Buoninconti A, Mandato C, Pepe A, Sperandeo MP, Del Gado R et al. The C677T mutation of the 5,1O-methylenetetrahydrofolate reductase gene is a moderate risk factor for spina bifida in Italy. Journal of Medical Genetics. 1998;35(12):1009-1013.
De Franchis, Raffaella ; Buoninconti, Anna ; Mandato, Claudia ; Pepe, Antonio ; Sperandeo, Maria Pia ; Del Gado, Roberto ; Capra, Valeria ; Salvaggio, Elio ; Andria, Generoso ; Mastroiacovo, Pierpaolo. / The C677T mutation of the 5,1O-methylenetetrahydrofolate reductase gene is a moderate risk factor for spina bifida in Italy. In: Journal of Medical Genetics. 1998 ; Vol. 35, No. 12. pp. 1009-1013.
@article{958b535a2cfa4d30aec5030354704e85,
title = "The C677T mutation of the 5,1O-methylenetetrahydrofolate reductase gene is a moderate risk factor for spina bifida in Italy",
abstract = "Objective: To estimate the risk for spina bifida associated with the common mutation C677T of the MTHFR gene in a country with a relatively low prevalence of NTDs. Design: Case-control study. Subjects: Cases: 203 living patients affected with spina bifida (173 myelomeningocele and 30 lipomeningocele); controls: 583 subjects (306 young adults and 277 unselected newborns) from northern and central-southern Italy. Setting: Cases: Three spina bifida centres; young adult controls: DNA banks; newborn controls: regional neonatal screening centres. Main outcome measures: Prevalence of the C677T genotypes in cases and controls by place of birth; odds ratios for spina bifida and estimated attributable fraction. Results: The prevalence of T/T, T/C, and C/C genotype was 16.6{\%}, 53.7{\%}, and 29.7{\%} in controls and 25.6{\%}, 43.8{\%}, and 30.6{\%} in cases, respectively. We found no differences between type of defect or place of birth. The odds ratio for spina bifida associated with the T/T genotype v C/C plus T/C was 1.73 (95{\%} CI 1.15, 2.59) and the corresponding attributable fraction was 10.8{\%}. No increased risk was found for heterozygous patients (OR = 0.79, 95{\%} CI 0.53-1.18). Conclusion: This study, as well as the meta-analysis we updated, shows that homozygosity for the MTHFR C677T mutation is a moderate risk factor in Europe, and even in Italy where there is a relatively low prevalence of spina bifida. The estimated attributable fraction associated with this risk factor explains only a small proportion of cases preventable by periconceptional folic acid supplementation. Thus, other genes involved in folate-homocysteine metabolism, their interaction, and the interaction between genetic and environmental factors should be investigated further.",
keywords = "Folic acid, Meta-analysis, MTHFR, Spina bifida",
author = "{De Franchis}, Raffaella and Anna Buoninconti and Claudia Mandato and Antonio Pepe and Sperandeo, {Maria Pia} and {Del Gado}, Roberto and Valeria Capra and Elio Salvaggio and Generoso Andria and Pierpaolo Mastroiacovo",
year = "1998",
language = "English",
volume = "35",
pages = "1009--1013",
journal = "Journal of Medical Genetics",
issn = "0022-2593",
publisher = "BMJ Publishing Group",
number = "12",

}

TY - JOUR

T1 - The C677T mutation of the 5,1O-methylenetetrahydrofolate reductase gene is a moderate risk factor for spina bifida in Italy

AU - De Franchis, Raffaella

AU - Buoninconti, Anna

AU - Mandato, Claudia

AU - Pepe, Antonio

AU - Sperandeo, Maria Pia

AU - Del Gado, Roberto

AU - Capra, Valeria

AU - Salvaggio, Elio

AU - Andria, Generoso

AU - Mastroiacovo, Pierpaolo

PY - 1998

Y1 - 1998

N2 - Objective: To estimate the risk for spina bifida associated with the common mutation C677T of the MTHFR gene in a country with a relatively low prevalence of NTDs. Design: Case-control study. Subjects: Cases: 203 living patients affected with spina bifida (173 myelomeningocele and 30 lipomeningocele); controls: 583 subjects (306 young adults and 277 unselected newborns) from northern and central-southern Italy. Setting: Cases: Three spina bifida centres; young adult controls: DNA banks; newborn controls: regional neonatal screening centres. Main outcome measures: Prevalence of the C677T genotypes in cases and controls by place of birth; odds ratios for spina bifida and estimated attributable fraction. Results: The prevalence of T/T, T/C, and C/C genotype was 16.6%, 53.7%, and 29.7% in controls and 25.6%, 43.8%, and 30.6% in cases, respectively. We found no differences between type of defect or place of birth. The odds ratio for spina bifida associated with the T/T genotype v C/C plus T/C was 1.73 (95% CI 1.15, 2.59) and the corresponding attributable fraction was 10.8%. No increased risk was found for heterozygous patients (OR = 0.79, 95% CI 0.53-1.18). Conclusion: This study, as well as the meta-analysis we updated, shows that homozygosity for the MTHFR C677T mutation is a moderate risk factor in Europe, and even in Italy where there is a relatively low prevalence of spina bifida. The estimated attributable fraction associated with this risk factor explains only a small proportion of cases preventable by periconceptional folic acid supplementation. Thus, other genes involved in folate-homocysteine metabolism, their interaction, and the interaction between genetic and environmental factors should be investigated further.

AB - Objective: To estimate the risk for spina bifida associated with the common mutation C677T of the MTHFR gene in a country with a relatively low prevalence of NTDs. Design: Case-control study. Subjects: Cases: 203 living patients affected with spina bifida (173 myelomeningocele and 30 lipomeningocele); controls: 583 subjects (306 young adults and 277 unselected newborns) from northern and central-southern Italy. Setting: Cases: Three spina bifida centres; young adult controls: DNA banks; newborn controls: regional neonatal screening centres. Main outcome measures: Prevalence of the C677T genotypes in cases and controls by place of birth; odds ratios for spina bifida and estimated attributable fraction. Results: The prevalence of T/T, T/C, and C/C genotype was 16.6%, 53.7%, and 29.7% in controls and 25.6%, 43.8%, and 30.6% in cases, respectively. We found no differences between type of defect or place of birth. The odds ratio for spina bifida associated with the T/T genotype v C/C plus T/C was 1.73 (95% CI 1.15, 2.59) and the corresponding attributable fraction was 10.8%. No increased risk was found for heterozygous patients (OR = 0.79, 95% CI 0.53-1.18). Conclusion: This study, as well as the meta-analysis we updated, shows that homozygosity for the MTHFR C677T mutation is a moderate risk factor in Europe, and even in Italy where there is a relatively low prevalence of spina bifida. The estimated attributable fraction associated with this risk factor explains only a small proportion of cases preventable by periconceptional folic acid supplementation. Thus, other genes involved in folate-homocysteine metabolism, their interaction, and the interaction between genetic and environmental factors should be investigated further.

KW - Folic acid

KW - Meta-analysis

KW - MTHFR

KW - Spina bifida

UR - http://www.scopus.com/inward/record.url?scp=17344370082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17344370082&partnerID=8YFLogxK

M3 - Article

C2 - 9863598

AN - SCOPUS:17344370082

VL - 35

SP - 1009

EP - 1013

JO - Journal of Medical Genetics

JF - Journal of Medical Genetics

SN - 0022-2593

IS - 12

ER -